Enhanced Liquid Biopsy Platform
Oncology (Broad)
Platform ValidationActive
Key Facts
About Wobble Genomics
Wobble Genomics is an early-stage biotech (founded 2020) pioneering a liquid biopsy platform based on full-length, long-read RNA sequencing. Its core technologies, Level-Up (biochemical) and TAMA (bioinformatics), are designed to unlock and analyze low-abundance RNA from blood, revealing novel biomarkers for cancer. The company has presented early validation data at major conferences (SABCS 2025, ESMO 2025), demonstrating application in breast cancer (HER2 profiling) and platform robustness. It operates as a private, pre-revenue diagnostics platform company targeting a significant opportunity in non-invasive cancer testing.
View full company profileTherapeutic Areas
Other Oncology (Broad) Drugs
| Drug | Company | Phase |
|---|---|---|
| Functional Precision Oncology Platform Validation | Known Medicine | Pre-clinical |
| Clinical Trial Program | VitroScan | N/A (Diagnostic Validation) |
| Personalized Treatment Screening | Okomera | Pre-clinical |
| Preclinical Drug Discovery Services | Okomera | Pre-clinical |
| RWE Data Pipeline | Perthera | Commercial |
| Clinical Trial Matching Service | Perthera | Commercial |
| Live Tissue Biobanking Service | SpeciCare | Service |
| Ex Vivo Therapy Testing | SpeciCare | Research |
| Personalized Vaccine Support | SpeciCare | Research |
| Clinical Trial Matching & Access | SpeciCare | Service |
| Organoid Creation & Biobanking | SpeciCare | Research |